Puma Biotechnology Inc (PBYI) - Net Assets
Based on the latest financial reports, Puma Biotechnology Inc (PBYI) has net assets worth $130.34 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($216.30 Million) and total liabilities ($85.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PBYI asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $130.34 Million |
| % of Total Assets | 60.26% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -37.88% |
| Growth Volatility | 10498965.09 |
Puma Biotechnology Inc - Net Assets Trend (2007–2025)
This chart illustrates how Puma Biotechnology Inc's net assets have evolved over time, based on quarterly financial data. Also explore PBYI total assets for the complete picture of this company's asset base.
Annual Net Assets for Puma Biotechnology Inc (2007–2025)
The table below shows the annual net assets of Puma Biotechnology Inc from 2007 to 2025. For live valuation and market cap data, see Puma Biotechnology Inc (PBYI) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $130.34 Million | +41.48% |
| 2024-12-31 | $92.12 Million | +72.38% |
| 2023-12-31 | $53.44 Million | +147.33% |
| 2022-12-31 | $21.61 Million | +983.40% |
| 2021-12-31 | $-2.45 Million | +58.90% |
| 2020-12-31 | $-5.95 Million | -134.08% |
| 2019-12-31 | $17.46 Million | -49.10% |
| 2018-12-31 | $34.31 Million | -35.64% |
| 2017-12-31 | $53.30 Million | -74.60% |
| 2016-12-31 | $209.82 Million | +1.85% |
| 2015-12-31 | $206.01 Million | +76.00% |
| 2014-12-31 | $117.05 Million | +39.36% |
| 2013-12-31 | $83.99 Million | -34.85% |
| 2012-12-31 | $128.91 Million | +137.08% |
| 2011-12-31 | $54.37 Million | +39400287.68% |
| 2009-12-31 | $138.00 | +106.34% |
| 2008-12-31 | $-2.18K | -- |
| 2007-12-31 | $0.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Puma Biotechnology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 128377500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $36.00K | 0.03% |
| Other Components | $1.41 Billion | 1084.91% |
| Total Equity | $130.34 Million | 100.00% |
Puma Biotechnology Inc Competitors by Market Cap
The table below lists competitors of Puma Biotechnology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nexxen International Ltd
NASDAQ:NEXN
|
$381.13 Million |
|
Sichuan Haowu Electromechanical Co Ltd
SHE:000757
|
$381.19 Million |
|
Lumina Gold Corp
V:LUM
|
$381.31 Million |
|
Claros Mortgage Trust Inc
NYSE:CMTG
|
$381.40 Million |
|
Altshuler Shaham Financial LTD
TA:ALTF
|
$381.01 Million |
|
VTEX
NYSE:VTEX
|
$380.90 Million |
|
Future Generation Australia Ltd
AU:FGX
|
$380.90 Million |
|
Komipharm International Co. Ltd
KQ:041960
|
$380.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Puma Biotechnology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 92,125,000 to 130,340,000, a change of 38,215,000 (41.5%).
- Net income of 31,111,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 30,000.
- Other factors increased equity by 7,074,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $31.11 Million | +23.87% |
| Other Comprehensive Income | $30.00K | +0.02% |
| Other Changes | $7.07 Million | +5.43% |
| Total Change | $- | 41.48% |
Book Value vs Market Value Analysis
This analysis compares Puma Biotechnology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.91x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 209.16x to 2.91x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $0.04 | $7.49 | x |
| 2008-12-31 | $0.00 | $7.49 | x |
| 2009-12-31 | $0.00 | $7.49 | x |
| 2010-12-31 | $0.00 | $7.49 | x |
| 2011-12-31 | $2.71 | $7.49 | x |
| 2012-12-31 | $5.93 | $7.49 | x |
| 2013-12-31 | $2.93 | $7.49 | x |
| 2014-12-31 | $3.90 | $7.49 | x |
| 2015-12-31 | $6.41 | $7.49 | x |
| 2016-12-31 | $6.30 | $7.49 | x |
| 2017-12-31 | $1.43 | $7.49 | x |
| 2018-12-31 | $0.90 | $7.49 | x |
| 2019-12-31 | $0.45 | $7.49 | x |
| 2020-12-31 | $-0.15 | $7.49 | x |
| 2021-12-31 | $-0.06 | $7.49 | x |
| 2022-12-31 | $0.48 | $7.49 | x |
| 2023-12-31 | $1.12 | $7.49 | x |
| 2024-12-31 | $1.88 | $7.49 | x |
| 2025-12-31 | $2.57 | $7.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Puma Biotechnology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.87%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.62%
- • Asset Turnover: 1.06x
- • Equity Multiplier: 1.66x
- Recent ROE (23.87%) is above the historical average (-971.37%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -1072.71% | 0.00% | 0.00x | 1.00x | $-15.23 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.87K |
| 2009 | -12200.00% | 0.00% | 0.00x | 17.45x | $-16.85K |
| 2010 | -3458.01% | 0.00% | 0.00x | 1.00x | $-16.02K |
| 2011 | -18.82% | 0.00% | -0.01x | 1.02x | $-15.67 Million |
| 2012 | -57.64% | 0.00% | 0.00x | 1.18x | $-87.19 Million |
| 2013 | -65.08% | 0.00% | 0.00x | 1.24x | $-63.06 Million |
| 2014 | -121.37% | 0.00% | 0.00x | 1.39x | $-153.70 Million |
| 2015 | -116.17% | 0.00% | 0.00x | 1.16x | $-259.90 Million |
| 2016 | -131.55% | 0.00% | 0.00x | 1.20x | $-296.98 Million |
| 2017 | -547.82% | -1054.15% | 0.17x | 3.11x | $-297.33 Million |
| 2018 | -331.14% | -45.26% | 0.97x | 7.55x | $-117.03 Million |
| 2019 | -432.89% | -27.77% | 1.16x | 13.45x | $-77.34 Million |
| 2020 | 0.00% | -26.65% | 0.92x | 0.00x | $-59.40 Million |
| 2021 | 0.00% | -11.51% | 1.12x | 0.00x | $-28.88 Million |
| 2022 | 0.01% | 0.00% | 1.03x | 10.28x | $-2.16 Million |
| 2023 | 40.40% | 9.16% | 1.02x | 4.31x | $16.25 Million |
| 2024 | 32.87% | 13.14% | 1.08x | 2.32x | $21.07 Million |
| 2025 | 23.87% | 13.62% | 1.06x | 1.66x | $18.08 Million |
Industry Comparison
This section compares Puma Biotechnology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Puma Biotechnology Inc (PBYI) | $130.34 Million | -1072.71% | 0.66x | $381.06 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined wit… Read more